MX2012007875A - Uso de derivados de 5-[[2, 3-dimetil-2h-indazol-6-il)-metilamino]- 2-pirimidil] amino]-2-metilbencensulfonamida en transtornos oculares. - Google Patents
Uso de derivados de 5-[[2, 3-dimetil-2h-indazol-6-il)-metilamino]- 2-pirimidil] amino]-2-metilbencensulfonamida en transtornos oculares.Info
- Publication number
- MX2012007875A MX2012007875A MX2012007875A MX2012007875A MX2012007875A MX 2012007875 A MX2012007875 A MX 2012007875A MX 2012007875 A MX2012007875 A MX 2012007875A MX 2012007875 A MX2012007875 A MX 2012007875A MX 2012007875 A MX2012007875 A MX 2012007875A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment method
- hydrates
- administration
- patient
- directed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a métodos para el tratamiento de trastornos de angiogénesis ocular o filtración vascular en un paciente, mediante la administración de inhibidores adecuados, incluyendo pazopanib o sales farmacéuticamente aceptables o hidratos del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29274710P | 2010-01-06 | 2010-01-06 | |
PCT/US2011/020231 WO2011085007A1 (en) | 2010-01-06 | 2011-01-05 | Treatment method |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012007875A true MX2012007875A (es) | 2012-08-03 |
Family
ID=44305773
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012007875A MX2012007875A (es) | 2010-01-06 | 2011-01-05 | Uso de derivados de 5-[[2, 3-dimetil-2h-indazol-6-il)-metilamino]- 2-pirimidil] amino]-2-metilbencensulfonamida en transtornos oculares. |
Country Status (20)
Country | Link |
---|---|
US (1) | US20130012531A1 (es) |
EP (1) | EP2521550A4 (es) |
JP (1) | JP2013516472A (es) |
KR (1) | KR20120125244A (es) |
CN (1) | CN102781450A (es) |
AU (1) | AU2011203706A1 (es) |
BR (1) | BR112012016673A2 (es) |
CA (1) | CA2786328A1 (es) |
CL (1) | CL2012001852A1 (es) |
CO (1) | CO6561789A2 (es) |
DO (1) | DOP2012000174A (es) |
EA (1) | EA201290603A1 (es) |
IL (1) | IL220594A0 (es) |
MA (1) | MA33991B1 (es) |
MX (1) | MX2012007875A (es) |
PE (1) | PE20121523A1 (es) |
SG (1) | SG181826A1 (es) |
TW (1) | TW201201808A (es) |
UY (1) | UY33164A (es) |
WO (1) | WO2011085007A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
UY33367A (es) * | 2010-05-05 | 2011-10-31 | Glaxo Wellcome Mfg Pte Ltd | Composiciones farmacéuticas y métodos para su elaboración |
CA2818612C (en) | 2010-11-19 | 2020-12-29 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
EP2844250B1 (en) * | 2012-05-01 | 2017-11-08 | Translatum Medicus Inc. | Methods for treating and diagnosing blinding eye diseases |
EP2968113B8 (en) | 2013-03-14 | 2020-10-28 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
CN105659085B (zh) | 2013-08-28 | 2018-12-07 | 中美冠科生物技术(太仓)有限公司 | 预测受试者对多激酶抑制剂的反应的基因表达标志及其使用方法 |
BR112017002466A2 (pt) | 2014-08-08 | 2017-12-05 | Forsight Vision4 Inc | formulações estáveis e solúveis de inibidores da tirosina cinase do receptor, e métodos para a sua preparação |
EP4335418A3 (en) * | 2015-06-06 | 2024-05-22 | Cloudbreak Therapeutics, LLC | Compositions and methods for treating pterygium |
US10323349B2 (en) * | 2015-09-25 | 2019-06-18 | Kyoudojyutaku Co., Ltd. | Washing system |
EP3463225A4 (en) | 2016-06-02 | 2020-03-11 | Cloudbreak Therapeutics, LLC | COMPOSITIONS AND METHODS OF USING NINTEDANIB TO IMPROVE THE SUCCESS RATE OF GLAUCOMA SURGERY |
EP3990433A4 (en) | 2019-06-25 | 2023-07-26 | Translatum Medicus Inc. | METHODS FOR THE MANUFACTURE OF 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE430742T1 (de) * | 2000-12-21 | 2009-05-15 | Smithkline Beecham Corp | Pyrimidinamine als angiogenesemodulatoren |
NZ568075A (en) * | 2005-11-29 | 2010-12-24 | Smithkline Beecham Corp | Treatment of ocular neovascular disorders such as macular degeneration, angoid streaks, uveitis and macular edema |
US20090004213A1 (en) * | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
US8334239B2 (en) * | 2007-07-10 | 2012-12-18 | The Board Of Regents Of The University Of Texas System | High affinity VEGF-receptor antagonists |
US20090325959A1 (en) * | 2008-06-26 | 2009-12-31 | Vittitow Jason L | Method for treating ophthalmic diseases using rho kinase inhibitor compounds |
AU2010273254A1 (en) * | 2009-07-16 | 2012-02-02 | Glaxo Wellcome Manufacturing Pte Ltd | Treatment method |
-
2011
- 2011-01-04 TW TW100100228A patent/TW201201808A/zh unknown
- 2011-01-04 UY UY0001033164A patent/UY33164A/es not_active Application Discontinuation
- 2011-01-05 AU AU2011203706A patent/AU2011203706A1/en not_active Abandoned
- 2011-01-05 KR KR1020127017481A patent/KR20120125244A/ko not_active Application Discontinuation
- 2011-01-05 BR BR112012016673A patent/BR112012016673A2/pt not_active IP Right Cessation
- 2011-01-05 CN CN2011800126697A patent/CN102781450A/zh active Pending
- 2011-01-05 PE PE2012000913A patent/PE20121523A1/es not_active Application Discontinuation
- 2011-01-05 EA EA201290603A patent/EA201290603A1/ru unknown
- 2011-01-05 CA CA2786328A patent/CA2786328A1/en not_active Abandoned
- 2011-01-05 MX MX2012007875A patent/MX2012007875A/es not_active Application Discontinuation
- 2011-01-05 US US13/518,407 patent/US20130012531A1/en not_active Abandoned
- 2011-01-05 MA MA35126A patent/MA33991B1/fr unknown
- 2011-01-05 SG SG2012045431A patent/SG181826A1/en unknown
- 2011-01-05 WO PCT/US2011/020231 patent/WO2011085007A1/en active Application Filing
- 2011-01-05 JP JP2012548091A patent/JP2013516472A/ja not_active Withdrawn
- 2011-01-05 EP EP11732087.9A patent/EP2521550A4/en not_active Withdrawn
-
2012
- 2012-06-19 DO DO2012000174A patent/DOP2012000174A/es unknown
- 2012-06-21 IL IL220594A patent/IL220594A0/en unknown
- 2012-07-06 CO CO12113697A patent/CO6561789A2/es not_active Application Discontinuation
- 2012-07-06 CL CL2012001852A patent/CL2012001852A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP2521550A1 (en) | 2012-11-14 |
CN102781450A (zh) | 2012-11-14 |
UY33164A (es) | 2011-08-31 |
PE20121523A1 (es) | 2012-12-12 |
US20130012531A1 (en) | 2013-01-10 |
WO2011085007A1 (en) | 2011-07-14 |
TW201201808A (en) | 2012-01-16 |
JP2013516472A (ja) | 2013-05-13 |
AU2011203706A1 (en) | 2012-07-12 |
MA33991B1 (fr) | 2013-02-01 |
EA201290603A1 (ru) | 2013-03-29 |
KR20120125244A (ko) | 2012-11-14 |
SG181826A1 (en) | 2012-07-30 |
CA2786328A1 (en) | 2011-07-14 |
IL220594A0 (en) | 2012-08-30 |
CL2012001852A1 (es) | 2012-11-30 |
CO6561789A2 (es) | 2012-11-15 |
DOP2012000174A (es) | 2012-12-15 |
BR112012016673A2 (pt) | 2018-06-05 |
EP2521550A4 (en) | 2013-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2012007875A (es) | Uso de derivados de 5-[[2, 3-dimetil-2h-indazol-6-il)-metilamino]- 2-pirimidil] amino]-2-metilbencensulfonamida en transtornos oculares. | |
PH12016502355A1 (en) | Pharmaceutical composition | |
MX363243B (es) | Composiciones para tratar cáncer y usos de dichas composiciones. | |
MD4539C1 (ro) | 4-Fenilpiridine substituite pentru tratamentul bolilor asociate cu receptorul NK-1 | |
MY191100A (en) | Treatment for lipodystrophy | |
EA201190337A1 (ru) | Способ лечения | |
SG195257A1 (en) | Anti-thrombotic compounds | |
MX354535B (es) | TRATAMIENTO DE INFARTO DE MIOCARDIO USANDO ANTAGONISTAS DE TGF-ß. | |
MX2013008340A (es) | Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer. | |
MX2021014120A (es) | Tratamiento de los sintomas asociados a terapia privacion de androgenos. | |
MX348723B (es) | Combinaciones de solifenacina y estimulantes salivales para el tratamiento de la vejiga hiperactiva. | |
WO2011133826A3 (en) | Method for treating pancreatic cancer | |
PH12015501211A1 (en) | Use of pidotimod to treat atopic dermatitis | |
MX2014000870A (es) | Composiciones farmaceuticas que comprenden 4-bromo-n-(imidazolidin -2-iliden)-1h-benzimidazol-5-amina para tratar enfermedades de la retina. | |
GB201107576D0 (en) | Novel compounds and methods for use in medicine | |
UA56440U (ru) | Способ лечения бактериального хронического одонтогенного остеомиелита челюсти | |
UA55818U (ru) | Способ лечения хронических заболеваний роговицы | |
MY165030A (en) | Treatment of seborrhoea | |
UA68841U (ru) | Способ хирургического лечения варикоцеле | |
NZ623275A (en) | Treatment of ocular disease | |
UA69982U (ru) | Способ лечения рецидивирующей формы герпетической инфекции | |
UA69624U (uk) | Спосіб профілактики загострення хронічного бронхіту у хворих зі сполученим перебігом з пептичною виразкою дванадцятипалої кишки | |
UA66494U (ru) | Способ лечения холедохолитиаза | |
UA74055U (ru) | Способ хирургического лечения рефрактерных форм глаукомы | |
UA67427U (ru) | Способ лечения фиброзно-кавернозных форм органного туберкулеза |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |